ATE464048T1 - Behandlung von alzheimer-krankheit und verwandten zuständen - Google Patents
Behandlung von alzheimer-krankheit und verwandten zuständenInfo
- Publication number
- ATE464048T1 ATE464048T1 AT04767944T AT04767944T ATE464048T1 AT E464048 T1 ATE464048 T1 AT E464048T1 AT 04767944 T AT04767944 T AT 04767944T AT 04767944 T AT04767944 T AT 04767944T AT E464048 T1 ATE464048 T1 AT E464048T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- alzheimer
- disease
- related conditions
- amyloid
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/96—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0318552A GB0318552D0 (en) | 2003-08-07 | 2003-08-07 | Therapeutic treatment |
| GB0408100A GB0408100D0 (en) | 2004-04-08 | 2004-04-08 | Therapeutic agents |
| PCT/GB2004/003286 WO2005013985A1 (en) | 2003-08-07 | 2004-07-29 | Treatment for alzheimer's disease and related conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE464048T1 true ATE464048T1 (de) | 2010-04-15 |
Family
ID=34137751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04767944T ATE464048T1 (de) | 2003-08-07 | 2004-07-29 | Behandlung von alzheimer-krankheit und verwandten zuständen |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20080153817A1 (de) |
| EP (1) | EP1656141B1 (de) |
| JP (1) | JP4769718B2 (de) |
| AT (1) | ATE464048T1 (de) |
| AU (1) | AU2004262970B2 (de) |
| CA (1) | CA2534240A1 (de) |
| DE (1) | DE602004026597D1 (de) |
| WO (1) | WO2005013985A1 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7019022B2 (en) | 2003-12-15 | 2006-03-28 | Merck Frosst Canada & Co. | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives |
| AU2005230897B2 (en) * | 2004-04-02 | 2011-03-03 | Merck Sharp & Dohme Corp. | Asymmetric hydrogenation process useful for the preparation of cycloalkanoindole derivatives |
| GB0410238D0 (en) * | 2004-05-07 | 2004-06-09 | Merck Sharp & Dohme | Therapeutic agents |
| GB0522908D0 (en) * | 2005-11-10 | 2005-12-21 | Merck Sharp & Dohme | Therapeutic agents |
| CA2676715A1 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| EP2367826A4 (de) | 2008-11-06 | 2012-07-04 | Astrazeneca Ab | Amyloid-beta-modulatoren |
| WO2010071741A1 (en) | 2008-12-16 | 2010-06-24 | Merck Sharp & Dohme Corp. | Triazole derivatives for treatment of alzheimer's disease |
| WO2014195321A1 (en) | 2013-06-04 | 2014-12-11 | Acturum Life Science AB | Triazole compounds and their use as gamma secretase modulators |
| PL3004079T3 (pl) | 2013-06-04 | 2018-07-31 | Acturum Real Estate Ab | Związki pirymidyny i ich zastosowanie jako modulatorów sekretazy gamma |
| US9718805B2 (en) | 2013-06-04 | 2017-08-01 | Acturum Life Science AB | Triazole compounds and their use as gamma secretase modulators |
| WO2019121143A1 (en) | 2017-12-20 | 2019-06-27 | Basf Se | Substituted cyclopropyl derivatives |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5021447A (en) * | 1986-01-23 | 1991-06-04 | Merck Frosst Canada, Inc. | Tetrahydrocarbazole 1-alkanoic acids and pharmaecutical compositions |
| US4808608A (en) * | 1986-01-23 | 1989-02-28 | Merck & Co., Inc. | Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use |
| DE3768097D1 (de) * | 1986-01-23 | 1991-04-04 | Merck Frosst Canada Inc | Tetrahydrocarbazol-1-alkansaeuren. |
| EP0307077A1 (de) * | 1987-07-21 | 1989-03-15 | Merck Frosst Canada Inc. | Tetrahydrocarbazole zur Verbesserung der Cyclosporintherapie |
| WO1999025340A1 (en) * | 1997-11-14 | 1999-05-27 | Eli Lilly And Company | Treatment for alzheimer's disease |
| WO2000006560A1 (en) * | 1998-07-30 | 2000-02-10 | Warner-Lambert Company | Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases |
| US6410583B1 (en) * | 2000-07-25 | 2002-06-25 | Merck Frosst Canada & Co. | Cyclopentanoindoles, compositions containing such compounds and methods of treatment |
| CA2357450A1 (en) * | 2000-09-29 | 2002-03-29 | Warner-Lambert Company | Phenoxazine analogs useful as amyloid aggregation inhibitors and treatment of alzheimer's disease and disorders related to amyloidosis |
| CA2465534C (en) * | 2000-11-02 | 2009-10-27 | Nigel H. Greig | Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof |
| AR038136A1 (es) * | 2002-01-24 | 2004-12-29 | Merck Frosst Canada Inc | Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento |
-
2004
- 2004-07-29 AT AT04767944T patent/ATE464048T1/de not_active IP Right Cessation
- 2004-07-29 AU AU2004262970A patent/AU2004262970B2/en not_active Ceased
- 2004-07-29 WO PCT/GB2004/003286 patent/WO2005013985A1/en not_active Ceased
- 2004-07-29 CA CA002534240A patent/CA2534240A1/en not_active Abandoned
- 2004-07-29 EP EP04767944A patent/EP1656141B1/de not_active Expired - Lifetime
- 2004-07-29 JP JP2006522393A patent/JP4769718B2/ja not_active Expired - Fee Related
- 2004-07-29 DE DE602004026597T patent/DE602004026597D1/de not_active Expired - Lifetime
- 2004-07-29 US US10/566,844 patent/US20080153817A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1656141B1 (de) | 2010-04-14 |
| WO2005013985A1 (en) | 2005-02-17 |
| US20080153817A1 (en) | 2008-06-26 |
| DE602004026597D1 (de) | 2010-05-27 |
| EP1656141A1 (de) | 2006-05-17 |
| AU2004262970A1 (en) | 2005-02-17 |
| CA2534240A1 (en) | 2005-02-17 |
| JP4769718B2 (ja) | 2011-09-07 |
| JP2007501778A (ja) | 2007-02-01 |
| AU2004262970B2 (en) | 2010-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE409176T1 (de) | 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen | |
| GB0223038D0 (en) | Therapeutic compounds | |
| GB0225474D0 (en) | Therapeutic agents | |
| ATE396174T1 (de) | Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| DE602004020072D1 (de) | 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen | |
| GB0318447D0 (en) | Therapeutic agents | |
| TW200420550A (en) | Thiazole compounds for the treatment of neurodegenerative disorders | |
| DE60303238D1 (de) | Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten | |
| DE60218493D1 (de) | Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten | |
| GB0423356D0 (en) | Therapeutic agents | |
| ATE383853T1 (de) | Arylessigsäuren und verwandte verbindungen zur behandlung von alzheimer-krankheit | |
| ATE389395T1 (de) | Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson | |
| DE60318839D1 (de) | 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten | |
| DE60312736D1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
| DE60204466D1 (de) | Integrinhemmer zur behandlung von augenkrankheiten | |
| ATE446285T1 (de) | Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3- thiosubstituierte indol-2-alkinsäuren | |
| ATE464048T1 (de) | Behandlung von alzheimer-krankheit und verwandten zuständen | |
| MY139368A (en) | Novel cyclohexyl sulphones | |
| TR200200278T2 (tr) | Kalsilitik bileşimler | |
| ATE437855T1 (de) | (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit | |
| ATE496534T1 (de) | Difluorierte piperidine zur behandlung von morbus alzheimer und verwandten leiden | |
| ATE330596T1 (de) | Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen | |
| DE602004030661D1 (de) | Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis | |
| DE60318081D1 (de) | Verwendung von brimonidine zur behandlung von dementia und morbus parkinson | |
| DE602004024992D1 (de) | Verwendung von pyrazolopyridinen zur behandlung von kognitiven defiziten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |